Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APPL2 siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
APPL2 siRNA is a research-grade gene-silencing reagent designed to knock down the expression of the APPL2 gene (Adaptor Protein, Phosphotyrosine Interacting With PH Domain And Leucine Zipper 2). APPL2 is a multifunctional endocytic adapter protein involved in endocytosis and cellular signaling pathways, including the AKT pathway. In laboratory studies, particularly in glioblastoma multiforme (GBM) models, silencing APPL2 with siRNA has been shown to reduce cell survival, inhibit proliferation, and enhance apoptosis. The reagent is primarily sold by laboratory supply companies such as Santa Cruz Biotechnology and MedChemExpress for research use only and is not currently being developed as a clinical therapeutic.
- Other names
- APPL2 small interfering RNAAPPL-2 small interfering RNAAPPL 2 small interfering RNA
02
Targets
IFIH1 (MDA5)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on APPL2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APPL2 siRNA.